Compare SiTime Corporation (SITM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SiTime Corporation vs TG Therapeutics Inc — how do they compare? SiTime Corporation trades at $685 (market cap $20.05B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: SiTime Corporation is far larger — about 2.6× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| SITM | TGTX | |
|---|---|---|
Market Cap | $20.05B | $7.64B |
Sector | Technology | Health |
52-Week High | $901.60 | $59.06 |
52-Week Low | $212.77 | $26.94 |
Enterprise Value | $19.45B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SITM trades at $680.52, down 1.37% on the day, with a bullish technical outlook supported by moving averages and key resistance at $687. The company reported strong Q2 2026 earnings of $2.34 per share, beating estimates, with revenue surging 127% year-over-year driven by AI infrastructure demand. Analyst consensus is unanimously bullish with a $870 price target, reflecting optimism around the Renesas acquisition and AI timing growth.
The outlook for SITM is positive given robust earnings beats, AI-driven revenue expansion, and solid institutional support. However, risks include premium valuation multiples, integration challenges from the Renesas deal, and dependence on cyclical tech spending. Investors should weigh high growth potential against execution risks in a competitive semiconductor market.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
